Serum testosterone level, testosterone replacement treatment, and prostate cancer

Advances in Urology

Volumn , Issue , 2013, Pages

  Atan, Ali ^a   Tuncel, Altug ^b   Yesil, Suleyman ^a   Balbay, Derya ^c  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c MEMORIAL HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885665119     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2013/275945     Document Type: Article

References (65)

1. He W., Sengupta M., Velkoff V. A., DeBarros K. A., Census Bureau U. S., Current Population Reports 2005 Washington, DC, USA U.S. Government Printing Office
2. Roehrborn C. G., Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Review Urology 2008 10 1 14 25
3. Schreiber G., Ziemer M., The aging male-diagnosis and therapy of late-onset hypogonadism. Journal der Deutschen Dermatologischen Gesellschaft 2008 6 4 273 279
4. Gray A., Feldman H. A., McKinlay J. B., Longcope C., Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism 1991 73 5 1016 1025 2-s2.0-0025884064 (Pubitemid 21901140)
5. Harman S. M., Metter E. J., Tobin J. D., Pearson J., Blackman M. R., Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Journal of Clinical Endocrinology and Metabolism 2001 86 2 724 731 2-s2.0-0035097033 10.1210/jc.86.2.724 (Pubitemid 32207487)
6. Araujo A. B., Esche G. R., Kupelian V., O'Donnell A. B., Travison T. G., Williams R. E., Clark R. V., McKinlay J. B., Prevalence of symptomatic androgen deficiency in men. Journal of Clinical Endocrinology and Metabolism 2007 92 11 4241 4247 2-s2.0-35948996162 10.1210/jc.2007-1245 (Pubitemid 350074738)
7. Wu F. C. W., Tajar A., Pye S. R., Silman A. J., Finn J. D., O'Neill T. W., Bartfai G., Casanueva F., Forti G., Giwercman A., Huhtaniemi I. T., Kula K., Punab M., Boonen S., Vanderschueren D., Petrone L., Cilotti A., Borghs H., Slowikowska-Hilczer J., Walczak-Jedrzejowska R., Wu F., Silman A., O'Neill T., Finn J., Steer P., Lee D., Pye S., Ocampo M., Lage M., Bartfai G., Földesi I., Fejes I., Korrovitz P., Jiang M., Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. Journal of Clinical Endocrinology and Metabolism 2008 93 7 2737 2745 2-s2.0-47549107694 10.1210/jc.2007-1972 (Pubitemid 352008544)
8. Morgentaler A., Testosterone replacement therapy and prostate cancer. Urologic Clinics of North America 2007 34 4 555 563 2-s2.0-35648968683 10.1016/j.ucl.2007.08.002 (Pubitemid 350029943)
9. Huggins C., Hodges C. V., Studies on PCa I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1941 1 4 293 297
10. Khera M., Androgen replacement therapy after prostate cancer treatment. Current Urology Reports 2010 11 6 393 399 2-s2.0-77958086445 10.1007/s11934-010-0143-3
11. Stattin P., Lumme S., Tenkanen L., Alfthan H., Jellum E., Hallmans G., Thoresen S., Hakulinen T., Luostarinen T., Lehtinen M., Dillner J., Stenman U.-H., Hakama M., High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. International Journal of Cancer 2004 108 3 418 424 2-s2.0-10744229508 10.1002/ijc.11572 (Pubitemid 37549608)
12. Morgentaler A., Bruning C. O. III, DeWolf W. C., Occult prostate cancer in men with low serum testosterone levels. Journal of the American Medical Association 1996 276 23 1904 1906 2-s2.0-0029856354 10.1001/jama.276.23.1904 (Pubitemid 26419188)
13. Hoffman M. A., DeWolf W. C., Morgentaler A., Is low serum free testosterone a marker for high grade prostate cancer? Journal of Urology 2000 163 3 824 827 2-s2.0-0033950926 (Pubitemid 30091624)
14. Massengill J. C., Sun L., Moul J. W., Wu H., McLeod D. G., Amling C., Lance R., Foley J., Sexton W., Kusuda L., Chung A., Soderdahl D., Donahue T., Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. Journal of Urology 2003 169 5 1670 1675 2-s2.0-0344406150 10.1097/01.ju.0000062674.43964.d0 (Pubitemid 36443468)
15. Ribeiro M., Ruff P., Falkson G., Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. American Journal of Clinical Oncology 1997 20 6 605 608 2-s2.0-0030690915 10.1097/00000421- 199712000-00015 (Pubitemid 27509888)
16. Chen S. S., Chen K.-K., Lin A. T. L., Chang Y.-H., Wu H. H., Chang L. S., The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU International 2002 89 7 710 713 2-s2.0-0036224481 10.1046/j.1464-410X.2002.02733.x (Pubitemid 34429536)
17. Yamamoto S., Yonese J., Kawakami S., Ohkubo Y., Tatokoro M., Komai Y., Takeshita H., Ishikawa Y., Fukui I., Preoperative Serum Testosterone Level as an Independent Predictor of Treatment Failure following Radical Prostatectomy{A figure is presented}. European Urology 2007 52 3 696 701 2-s2.0-34547156657 10.1016/j.eururo.2007.03.052 (Pubitemid 47126163)
18. Mearini L., Costantini E., Zucchi A., Mearini E., Bini V., Cottini E., Porena M., Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urologia Internationalis 2008 80 2 134 140 2-s2.0-41149141748 10.1159/000112602 (Pubitemid 351440505)
19. Snyder P. J., Peachey H., Berlin J. A., Hannoush P., Haddad G., Dlewati A., Santanna J., Loh L., Lenrow D. A., Holmes J. H., Kapoor S. C., Atkinson L. E., Strom B. L., Effects of testosterone replacement in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2000 85 8 2670 2677 2-s2.0-17744390362 10.1210/jc.85.8.2670 (Pubitemid 32269134)
20. Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumoto A. M., Snyder P. J., Weber T., Berman N., Hull L., Swerdloff R. S., Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2004 89 5 2085 2098 2-s2.0-2442543161 10.1210/jc.2003-032006 (Pubitemid 38619836)
21. Guay A. T., Jacobson J., The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. Journal of Sexual Medicine 2007 4 4 1046 1055 2-s2.0-34447526135 10.1111/j.1743-6109.2007.00530.x (Pubitemid 47079638)
22. Morales A., Black A. M., Emerson L. E., Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU International 2009 103 1 62 64 2-s2.0-57649148622 10.1111/j.1464-410X.2008.07882.x
23. Wang C., Nieschlag E., Swerdloff R., Behre H. M., Hellstrom W. J., Gooren L. J., Kaufman J. M., Legros J.-J., Lunenfeld B., Morales A., Morley J. E., Schulman C., Thompson I. M., Weidner W., Wu F. C. W., Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. European Urology 2009 55 1 121 130 2-s2.0-56249088599 10.1016/j.eururo.2008.08.033
24. Ho S. M., Damassa D., Kwan P. W., Seto H. S., Leav I., Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats. Journal of Andrology 1985 6 5 279 290 2-s2.0-0022119914
25. Traish A. M., Williams D. F., Hoffman N. D., Wotiz H. H., Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Progress in Clinical and Biological Research 1988 262 145 160 2-s2.0-0023714781
26. Marks L. S., Mazer N. A., Mostaghel E., Hess D. L., Dorey F. J., Epstein J. I., Veltri R. W., Makarov D. V., Partin A. W., Bostwick D. G., Macairan M. L., Nelson P. S., Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Journal of the American Medical Association 2006 296 19 2351 2361 2-s2.0-33750978404 10.1001/jama.296.19.2351 (Pubitemid 44749363)
27. Gann P. H., Hennekens C. H., Ma J., Longcope C., Stampfer M. J., Prospective study of sex hormone levels and risk of prostate cancer. Journal of the National Cancer Institute 1996 88 16 1118 1126 2-s2.0-0029813882 (Pubitemid 26274606)
28. Parsons J. K., Carter H. B., Platz E. A., Wright E. J., Landis P., Metter E. J., Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiology Biomarkers and Prevention 2005 14 9 2257 2260 2-s2.0-27744598614 10.1158/1055-9965.EPI-04-0715 (Pubitemid 41603276)
29. Morgentaler A., Rhoden E. L., Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006 68 6 1263 1267 2-s2.0-33845329200 10.1016/j.urology.2006.08.1058 (Pubitemid 44880344)
30. Thompson I. M., Pauler D. K., Goodman P. J., Tangen C. M., Lucia M. S., Parnes H. L., Minasian L. M., Ford L. G., Lippman S. M., Crawford E. D., Crowley J. J., Coltman C. A. Jr., Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. The New England Journal of Medicine 2004 350 22 2239 2321 2-s2.0-2442715038 10.1056/NEJMoa031918 (Pubitemid 38669206)
31. Roddam A. W., Allen N. E., Appleby P., Key T. J., Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 2008 100 3 170 183 2-s2.0-39149084101 10.1093/jnci/djm323 (Pubitemid 351480553)
32. Loughlin K. R., Richie J. P., Prostate cancer after exogenous testosterone treatment for impotence. Journal of Urology 1997 157 5, article 1845 2-s2.0-0030899378 10.1016/S0022-5347(01)64881-X (Pubitemid 27171790)
33. Gaylis F. D., Lin D. W., Ignatoff J. M., Amling C. L., Tutrone R. F., Cosgrove D. J., Prostate cancer in men using testosterone supplementation. Journal of Urology 2005 174 2 534 538 2-s2.0-22144488457 10.1097/01.ju. 0000165166.36280.60 (Pubitemid 40981594)
34. Gooren L. J. G., A ten-year safety study of the oral androgen testosterone undecanoate. Journal of Andrology 1994 15 3 212 215 2-s2.0-0028360993 (Pubitemid 24218140)
35. Cooper C. S., MacIndoe J. H., Perry P. J., Yates W. R., Williams R. D., The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. The Journal of Urology 1996 156 2 438 442 2-s2.0-0030211404 (Pubitemid 126445358)
36. Guay A. T., Perez J. B., Fitaihi W. A., Vereb M., Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocrine Practice 2000 6 2 132 138 2-s2.0-0034157553
37. Gerstenbluth R. E., Maniam P. N., Corty E. W., Seftel A. D., Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. Journal of Andrology 2002 23 6 922 926 2-s2.0-0036868435 (Pubitemid 36300984)
38. Rhoden E. L., Morgentaler A., Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine 2004 350 5 482 492 2-s2.0-1642458222 10.1056/NEJMra022251 (Pubitemid 38133769)
39. Calof O. M., Singh A. B., Lee M. L., Kenny A. M., Urban R. J., Tenover J. L., Bhasin S., Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. Journals of Gerontology A 2005 60 11 1451 1457 2-s2.0-29144469309 (Pubitemid 41798454)
40. McLaren D., Siemens D. R., Izard J., Black A., Morales A., Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome. BJU International 2008 102 9 1142 1146 2-s2.0-53849093066 10.1111/j.1464-410X.2008.07811.x
41. Shabsigh R., Crawford E. D., Nehra A., Slawin K. M., Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. International Journal of Impotence Research 2009 21 1 9 23 2-s2.0-58149512149 10.1038/ijir.2008.31
42. Feneley M. R., Carruthers M., Is testosterone treatment good for the prostate? Study of safety during long-term treatment. The Journal of Sexual Medicine 2012 9 8 2138 2149
43. Isbarn H., Pinthus J. H., Marks L. S., Montorsi F., Morales A., Morgentaler A., Schulman C., Testosterone and prostate cancer: revisiting old paradigms. European Urology 2009 56 1 48 56 2-s2.0-67349282280 10.1016/j.eururo.2009.03.088
44. Rhoden E. L., Morgentaler A., Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. Journal of Urology 2003 170 6 2348 2351 2-s2.0-0242692553 10.1097/01.ju.0000091104.71869.8e (Pubitemid 37413994)
45. Lefkowitz G. K., Taneja S. S., Brown J., Melamed J., Lepor H., Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. Journal of Urology 2002 168 4 1415 1418 2-s2.0-0036783557 (Pubitemid 35034136)
46. Morgentaler A., Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. Journal of Sexual Medicine 2009 6 2 574 577 2-s2.0-59349094677 10.1111/j.1743-6109.2008. 01066.x
47. Morgentaler A., Lipshultz L. I., Bennett R., Sweeney M., Avila D. Jr., Khera M., Testosterone therapy in men with untreated prostate cancer. Journal of Urology 2011 185 4 1256 1260 2-s2.0-79952698470 10.1016/j.juro.2010.11.084
48. Morales A., Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU International 2011 107 9 1369 1373 2-s2.0-79955394539 10.1111/j.1464-410X.2011. 10193.x
49. Bhasin S., Cunningham G. R., Hayes F. J., Matsumoto A. M., Snyder P. J., Swerdloff R. S., Montori V. M., Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2010 95 6 2536 2559 2-s2.0-77954409942 10.1210/jc.2009-2354
50. Kaufman J. M., Graydon R. J., Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. Journal of Urology 2004 172 3 920 922 2-s2.0-4143066958 10.1097/01.ju.0000136269.10161.32 (Pubitemid 39096423)
51. Agarwal P. K., Oefelein M. G., Testosterone replacement therapy after primary treatment for prostate cancer. Journal of Urology 2005 173 2 533 536 2-s2.0-12544256922 10.1097/01.ju.0000143942.55896.64
52. Mulhall J., Goldenberg L., Narus J., Gotto G., Tal R., Nabulsi O., Outcomes of testosterone supplementation in hypogonadal men following radical prostatectomy. The Journal of Urology 2008 179 4 426 427
53. Khera M., Grober E. D., Najari B., Colen J. S., Mohamed O., Lamb D. J., Lipshultz L. I., Testosterone replacement therapy following radical prostatectomy. Journal of Sexual Medicine 2009 6 4 1165 1170 2-s2.0-63849109998 10.1111/j.1743-6109.2009.01161.x
54. Isbarn H., Fisch M., Huland H., Graefen M., Sommer F., Testosterone treatment after radical prostatectomy for pathologically organ-confined prostate cancer: results from a multiinstitutional study. The Journal of Urology 2010 183 4 576 577
55. Pastuszak A. W., Pearlman A. M., Lai W. S., Godoy G., Sathyamoorthy K., Liu J. S., Miles B. J., Lipshultz L. I., Khera M., Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. The Journal of Urology 2013 190 2 639 644 10.1016/j.juro.2013.02.002
56. Leibowitz R. L., Dorff T. B., Tucker S., Symanowski J., Vogelzang N. J., Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU International 2010 105 10 1397 1401 2-s2.0-77951738484 10.1111/j.1464-410X. 2009.08980.x
57. Sarosdy M. F., Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007 109 3 536 541 2-s2.0-33846688614 10.1002/cncr.22438 (Pubitemid 46190961)
58. Davila H. H., Arison C. N., Hall M. K., Salup R., Lockhart J. L., Carrion R. E., Analysis of the PSA response after testosterone supplementation in patients who have previously received management for their localized prostate cancer. The Journal of Urology, Supplement 2008 179 428, abstract 1247
59. Pastuszak A. W., Pearlman A. M., Godoy G., Miles B. J., Lipshultz L. I., Khera M., Testosterone replacement therapy in the setting of prostate cancer treated with radiation. International Journal of Impotence Research 2013 25 1 24 28
60. Dohle G., Arver S., Bettocchi C., Members of the EAU guidelines office. guidelines on male hypogonadism. Proceedings of the 27th EAU Annual Congress 2012 Paris, France EAU Guidelines
61. Morgentaler A., Traish A. M., Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology 2009 55 2 310 321 2-s2.0-57649176913 10.1016/j.eururo.2008.09.024
62. Cooper C. S., Perry P. J., Sparks A. E. T., MacIndoe J. H., Yates W. R., Williams R. D., Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. Journal of Urology 1998 159 2 441 443 2-s2.0-0031975843 10.1016/S0022-5347(01)63944-2 (Pubitemid 28049252)
63. Bhasin S., Storer T. W., Berman N., Callegari C., Clevenger B., Phillips J., Bunnell T. J., Tricker R., Shirazi A., Casaburi R., The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. The New England Journal of Medicine 1996 335 1 1 7 2-s2.0-8944233864 10.1056/NEJM199607043350101 (Pubitemid 26230806)
64. Ramsay M., Schlegel P.,. AUA Updates Series Vol 29, Lesson 32, 2010
65. Greene K. L., Albertsen P. C., Babaian R. J., Carter H. B., Gann P. H., Han M., Kuban D. A., Sartor A. O., Stanford J. L., Zietman A., Carroll P., Prostate specific antigen best practice statement: 2009 update. Journal of Urology 2009 182 5 2232 2241 2-s2.0-70350450970 10.1016/j.juro.2009.07.093